SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Frequently asked questions
What sector does Sellas Life Sciences Group Inc (SLS) operate in?
Sellas Life Sciences Group Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Sellas Life Sciences Group Inc (SLS) current stock price?
As of the latest data, Sellas Life Sciences Group Inc stock price is $11.49, with a previous close of $11.53. Sellas Life Sciences Group Inc lost -$0.04 in the last trading session, representing a -0.35% loss.
What is Sellas Life Sciences Group Inc (SLS) current market capitalization?
Sellas Life Sciences Group Inc market cap is approximately 2.32 billion.
What is Sellas Life Sciences Group Inc (SLS) Earnings Per Share (EPS)?
The trailing EPS is -$0.22, and the forward EPS is -$0.10.
What is Sellas Life Sciences Group Inc (SLS) EBITDA?
Sellas Life Sciences Group Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -9.61 million.
Does Sellas Life Sciences Group Inc (SLS) pay dividends?
No. Sellas Life Sciences Group Inc does not pay a dividend.
What is Sellas Life Sciences Group Inc (SLS) beta (volatility) score?
Sellas Life Sciences Group Inc has a beta of 2.525, indicating very high volatility compared to the market.
